Therapeutic applications of induced pluripotent stem cells (iPSCs) have surged in recent years. Since the creation of human iPSCs in 2007, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2014. From 2014 to present, additional trials and physician-led studies employing human iPSC-derived cell types have been initiated across multiple geographies worldwide. [Read more…]
UniXell does first patient with an autologous iPSC-based cell therapy (UX-DA001) for Parkinson’s disease in Phase 1 study
SHANGHAI, May 23, 2025 — Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson’s disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson’s disease. [Read more…]
Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products to Accelerate Allogeneic Cell Therapy Development
MILPITAS, Calif. — Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which are designed to empower researchers developing next-generation allogeneic cell therapies. The ActiCells™ RUO Hypo hiPSCs (Cat.# ASE-9550) and the ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit (Cat.# AST-9650) offer powerful tools for building off-the-shelf therapies by combining reduced immunogenicity, robust pluripotency, and genome engineering readiness. They are an isogenic match to the forthcoming GMP-grade versions to offer a seamless path from early research to clinical development. [Read more…]
Pioneering the future of sports with iPS cells
FUNROOTS, I Peace, and Reju form a strategic alliance
FUNROOTS Co., Ltd. (Tokyo, Japan), I Peace, Inc. (California, USA), and Reju Inc. (Tokyo, Japan) entered a strategic partnership to integrate cutting-edge iPS cell technology into the sports industry, aiming to deliver innovative health management solutions, enhance athletic performance, and accelerate injury recovery, leveraging advancements in regenerative medicine. [Read more…]
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics
London, 03 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, and Gift of Life Biologics, (‘GOLB’) a leader in the provision of cellular starting material for cell therapies, announce a collaboration with GOLB as LIfT’s preferred partner for sourcing hematopoietic stem cells (HSCs) for the production of its clinical grade Immunomodulatory Alpha Neutrophils (IMANs), a first-in-class cell therapy designed to overcome treatment resistance in solid tumours as the Company prepares to initiate its clinical trials. [Read more…]
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 202
- Next Page »